Literature DB >> 30928658

Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma.

Claus Bachert1, Peter W Hellings2, Joaquim Mullol3, Robert M Naclerio4, Jingdong Chao5, Nikhil Amin5, Annette Grabher6, Brian N Swanson6, Jennifer D Hamilton6, Sophie Guillonneau7, Christine Taniou8, Donghui Zhang6, Gianluca Pirozzi6, Neil M H Graham5, Heribert Staudinger6, Leda P Mannent7, Asif Khan7.   

Abstract

Entities:  

Year:  2019        PMID： 30928658     DOI： 10.1016/j.jaip.2019.03.023

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  13 in total

Review 1.  New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.

Authors:  Esha Sehanobish; Mohammad Asad; Elina Jerschow
Journal:  Curr Opin Allergy Clin Immunol       Date:  2022-02-01

2.  Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.

Authors:  Hannah Wangberg; Samantha R Spierling Bagsic; Lilliana Osuna; Andrew A White
Journal:  J Allergy Clin Immunol Pract       Date:  2021-09-28

Review 3.  Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps.

Authors:  Renee R Koski; Luke Hill; Kylee Taavola
Journal:  J Pharm Technol       Date:  2022-07-11

Review 4.  Mechanisms of Dupilumab.

Authors:  Hani Harb; Talal A Chatila
Journal:  Clin Exp Allergy       Date:  2019-09-30       Impact factor: 5.018

5.  Biologics for chronic rhinosinusitis.

Authors:  Lee-Yee Chong; Patorn Piromchai; Steve Sharp; Kornkiat Snidvongs; Katie E Webster; Carl Philpott; Claire Hopkins; Martin J Burton
Journal:  Cochrane Database Syst Rev       Date:  2021-03-12

Review 6.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

Review 7.  Targetable pathogenic mechanisms in nasal polyposis.

Authors:  Alexander L Schneider; Robert P Schleimer; Bruce K Tan
Journal:  Int Forum Allergy Rhinol       Date:  2021-03-03       Impact factor: 5.426

8.  Biologics for chronic rhinosinusitis.

Authors:  Lee-Yee Chong; Patorn Piromchai; Steve Sharp; Kornkiat Snidvongs; Carl Philpott; Claire Hopkins; Martin J Burton
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

Review 9.  Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review.

Authors:  Letizia Nitro; Antonio Mario Bulfamante; Cecilia Rosso; Alberto Maria Saibene; Flavio Arnone; Giovanni Felisati; Carlotta Pipolo
Journal:  Acta Otorhinolaryngol Ital       Date:  2022-06       Impact factor: 2.618

10.  Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.

Authors:  Chien-Chia Chuang; Isabelle Guillemin; Claus Bachert; Stella E Lee; Peter W Hellings; Wytske J Fokkens; Nicolas Duverger; Chunpeng Fan; Nadia Daizadeh; Nikhil Amin; Leda P Mannent; Asif H Khan; Siddhesh Kamat
Journal:  Laryngoscope       Date:  2021-11-24       Impact factor: 2.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.